Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Rilzabrutinib

Generic Name: Rilzabrutinib

Drug Type: Small Molecule

Chemical Formula: C_₃₆H_₄₀FN_₉O_₃

CAS Number: 1575591-66-0

Unique Ingredient Identifier: 5G1WE425BI

Overview

Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.

Background

Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Rilzabrutinib for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine

Phase 2

Completed

Posted: 2021/11/04

Sponsor:Sanofi

ID:NCT05107115

Proof of Concept Study of Rilzabrutinib in Adult Participants With Moderate-to-severe Asthma

Phase 2

Completed

Posted: 2021/11/03

Sponsor:Sanofi

ID:NCT05104892

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

Phase 2

Completed

Posted: 2021/08/24

Sponsor:Sanofi

ID:NCT05018806

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

Phase 2

Active, not recruiting

Posted: 2021/08/12

Sponsor:Sanofi

ID:NCT05002777

Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants

Phase 1

Completed

Posted: 2021/02/10

Sponsor:

Principia Biopharma,...

ID:NCT04748926

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Global Thrombocytopenia Clinical Trials Market Sees Significant Growth in 2025

10 days ago

The global thrombocytopenia clinical trials landscape is expanding rapidly with over 25 pharmaceutical companies developing 25+ treatment therapies, according to recent market analysis.

FDA Approves First Targeted Therapy for IgG4-Related Disease: Amgen's UPLIZNA

11 days ago

The FDA has approved Amgen's UPLIZNA (inebilizumab-cdon) as the first and only targeted treatment specifically for IgG4-related disease, following positive results from the Phase III MITIGATE trial.

Sanofi Advances Respiratory Pipeline with Promising Amlitelimab Data in Heterogeneous Inflammatory Asthma

a month ago

Sanofi's amlitelimab demonstrated clinically meaningful efficacy in heterogeneous inflammatory asthma, showing over 70% reduction in exacerbations in patients with specific biomarkers at week 60 of the TIDE-Asthma phase 2 study.

UPLIZNA Becomes First FDA-Approved Treatment for IgG4-Related Disease, Reducing Flare Risk by 87%

2 months ago

The FDA has approved UPLIZNA (inebilizumab-cdon) as the first and only treatment for adults with IgG4-related disease, a chronic immune-mediated inflammatory condition that can cause permanent organ damage.

FDA Grants Orphan Drug Designation to Sanofi's Rilzabrutinib for Two Rare Diseases

2 months ago

The FDA has granted orphan drug designation to Sanofi's rilzabrutinib for warm autoimmune hemolytic anemia (wAIHA) and IgG4-related disease (IgG4-RD), two rare conditions with no currently approved treatments.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy